Release Date: 17-Jul-2024
IPH6101/SAR443579, a novel NK cell engager developed jointly by Innate Pharma and Sanofi through a research collaboration and license agreement, marks a pioneering leap in cancer therapy. This unique multi-specific antibody employs a novel strategy to efficiently engage NK cells in the eradication of CD123-expressing tumor cells, utilizing the activating receptors NKp46 and CD16. The implications for cancer treatment in the future are significant, as IPH6101 emerges with its unique mode of action and encouraging clinical results, implying a potential paradigm shift in the search for more effective and precise therapeutic approaches.
IPH6101 stands at the forefront as the first-in-class NKp46/CD16-based NK cell engager (NKCE) utilizing Innate’s proprietary multispecific antibody format, ANKET. This investigational drug has demonstrated remarkable anti-tumor activity in preclinical models, showcasing its potential to become a transformative force in cancer therapy. Supported by robust pharmacokinetic and pharmacodynamic (PK/PD) and safety data from non-human primate studies, IPH6101 has emerged as a promising drug candidate for further development. The successful integration of innovative technology and compelling preclinical results positions this investigational drug as a frontrunner in the evolving landscape of targeted cancer treatments.
In a phase 1/2 clinical trial, IPH6101 is being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia, or high risk myelodysplasia. IPH6101 was well tolerated up to dosages of 3000 g/kg once weekly, with demonstrated clinical benefit in patients with R/R AML, according to preliminary safety and efficacy results presented at the 2023 American Society of Clinical Oncology Meeting in June. Based on the results of this first-in-human trial, the US FDA granted IPH6101 Fast Track Designation for the treatment of hematological malignancies in December 2023, which will aid in the development and accelerated review of the candidate.
In conclusion, IPH6101/SAR443579 represents a groundbreaking advancement in the realm of cancer therapeutics, particularly offering newfound hope to patients with Acute Myeloid Leukemia (AML). As the first NKp46/CD16-based NK cell engager, its innovative approach has demonstrated significant anti-tumor activity in preclinical models, and compelling pharmacokinetic, pharmacodynamic and safety data from non-human primate studies further solidifies its potential as a transformative drug candidate for AML treatment. The pressing need for effective therapeutic options in AML patients adds crucial significance to the development of IPH6101, suggesting a promising future for this investigational NK cell engager and fostering optimism for the expansion of therapeutic avenues in the challenging landscape of AML treatment.
For Clinical Trials Information Contact